Chimeric Therapeutics (ASX:CHM) clinical stage T cell therapy biotech targeting glioblastoma
07 Jun 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's phase 1 trial results for its chlorotoxin CAR T (CLTX CAR T) cell therapy targeting glioblastoma.